Business Context and Reporting Period
MIRA Pharmaceuticals, Inc. (MIRA) filed a Form 8-K on July 12, 2024, reporting events occurring on July 8, 2024. The Company is an emerging growth company incorporated in Florida, with its common stock trading on the Nasdaq Capital Market under the symbol "MIRA."
Key Financial Metrics
This filing does not provide specific financial statements, revenue, profit, cash flow, or debt figures. The primary financial metric disclosed is the stock price performance triggering a listing deficiency: the closing bid price fell below $1.00 per share for 30 consecutive business days (May 22, 2024, through July 5, 2024).
Material Changes and Listing Status
On July 8, 2024, MIRA received a notice from Nasdaq indicating non-compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)) due to the stock price remaining below $1.00 for 30 consecutive days. The Company has been granted an initial 180-day compliance period ending January 6, 2025, to regain compliance. To do so, the stock must close at or above $1.00 for 10 consecutive business days prior to that date. Failure to comply may result in delisting, though an additional 180-day grace period may be available if other listing standards are met.
Outlook, Management Commentary, and Risks
Management outlined several strategic initiatives to support shareholder value and regain listing compliance:
- Ketamir-2: The Company plans to submit an Investigational New Drug (IND) application to the FDA by the end of 2024, with human clinical trials targeted for the first quarter of 2025.
- MIRA-55 Preclinical Results: New positive preclinical findings were reported for MIRA-55, a novel oral pharmaceutical marijuana analog. Testing indicates enhanced efficacy over THC at CB1 and CB2 receptors, consistent anxiolytic effects, stability across doses, and a reduced side effect profile.
- Strategic Partnerships: The Company is exploring licensing and development collaborations to de-risk its clinical pathway and enhance financial stability.
- Risks: There is no assurance the Company will regain compliance with Nasdaq listing requirements or that MIRA-55 will perform as anticipated in future clinical trials. Forward-looking statements regarding these milestones are subject to significant risks and uncertainties.
Investor Verification Checklist
- Verify the current stock price trend to assess the likelihood of meeting the $1.00 bid price requirement within the 180-day window.
- Confirm the timeline and status of the Ketamir-2 IND submission to the FDA.
- Review the detailed preclinical data for MIRA-55 to validate claims of enhanced efficacy and safety compared to THC.
- Monitor announcements regarding potential strategic partnerships or capital raises intended to improve financial stability.
- Check for any subsequent Nasdaq communications regarding the Company's compliance status or potential delisting notices.